February 21, 2022 – Current Report no. 5/2022 – Conclusion of a license purchase agreement

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.
Date: February 21, 2022, time: 22:18 p.m.
The Management Board of Celon Pharma S.A. ("Company") informs that on February 20, 2022, it learned about the conclusion of an agreement with the Salk Institute for Biological Studies ("Salk") on the purchase of a license for a patent package (Non-Exclusive Patent License Agreement, hereinafter: "Agreement") on treatments for metabolic disorders. Under the Agreement, Salk granted the Company a non-exclusive, transferable (under the terms of the Agreement) license for the commercial use or commercial sale of a licensed product for the treatment of diabetes and other metabolic diseases in humans.
The transaction will enable the Company to continue clinical work on the FGF1 protein analogue in the treatment of type 2 diabetes, and to extend development works to include other metabolic clinical indications. The research carried out by the Company so far has confirmed that the M43 candidate for an innovative anti-diabetic drug, developed under the FAIND project, based on the FGF1 protein analogue, may constitute a new, alternative and safe therapy for patients suffering from type 2 diabetes. It has shown a strong antidiabetic effect, and thanks to new, selective mutations in the FGF1 protein, it is free from carcinogenic effects. M43 is in the final stage of preclinical research, and in 2021 the Company filed a patent application for new FGF1 analogues, including M43. The current purchase is an important closing element towards the possession of full, unlimited commercialization rights for M43.
The FAIND project ("New diabetes therapy using an analogue of the FGF1 protein") led by Celon Pharma SA, as a leader, in cooperation with the University of Wrocław, received funding from the National Center for Research and Development in 2016 – the cost of the project was set at PLN 13.4 million, while the maximum amount of expenditure eligible for support for industrial research is PLN 9.9 million (see the Management Board's Report on the Activities of CELON PHARMA SA for 2016). The project implementation deadline is now extended to 2023 and includes the early stages of clinical trials.